New combo tackles tough myeloma
NCT ID NCT06465316
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—for people with multiple myeloma that has returned or is no longer responding to treatment. The goal is to find the safest and most effective dose. About 26 participants will receive the combination and be closely monitored for side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic Hospital in Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-••••
-
Moffitt Cancer Center
SUSPENDEDTampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Smilow Cancer Hospital Care Center - Guilford
RECRUITINGGuilford, Connecticut, 06437, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Smilow Cancer Hospital-Derby Care Center
RECRUITINGDerby, Connecticut, 06418, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Cancer Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Cancer Center-Overland Park
RECRUITINGOverland Park, Kansas, 66210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Hospital-Westwood Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VCU Massey Comprehensive Cancer Center
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale-New Haven Hospital North Haven Medical Center
RECRUITINGNorth Haven, Connecticut, 06473, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teclistamab and iberdomide
What this could lead to
If this works, it could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong
This is a very early phase 1 trial with only 26 people, so it's mainly checking safety and dosing. The combination may not work better than existing treatments, and side effects could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.